BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
October 24, 2024 08:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world comparative research on the use of oral, once-daily...
BioCryst to Report Third Quarter 2024 Financial Results on November 4
October 21, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on...
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
October 14, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO®...
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
October 10, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
–Presentations will demonstrate high adherence and persistence, sustained attack reductions and patient preference for oral, once-daily ORLADEYO for hereditary angioedema– RESEARCH TRIANGLE PARK,...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
October 02, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic— —Initial data from trial expected by end of 2025— RESEARCH...
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
September 30, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded...
BioCryst et l’Alliance pharmaceutique pancanadienne concluent avec succès les négociations au sujet de ORLADEYO (bérotralstat), un traitement oral à prise uniquotidienne pour la prévention des crises d’angio-œdème héréditaire
September 17, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RÉSERVÉ À UN PUBLIC CANADIEN TORONTO, 17 sept. 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq : BCRX) a annoncé aujourd’hui l’aboutissement des négociations avec l’Alliance...
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
September 17, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
INTENDED FOR CANADIAN AUDIENCES ONLY TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it successfully completed negotiations with the...
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
September 06, 2024 02:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word...